RHHBF

N/A

Roche Holding AG — PEG Ratio Analysis

—

PEG Ratio

Negative EPS growth — PEG not meaningful when earnings are declining

—

Growth Rate Source

Good Data Quality5-Year EPS CAGR

Current Price

$419.69

TTM EPS

$26.37

P/E Ratio

15.92

Growth Rate

-0.6%

5-Year EPS CAGR

Sector

Healthcare

Drug Manufacturers - General

Calculated

6/17/2026

10:24:10 AM

PEG Ratio Unavailable

Negative Growth — PEG not meaningful

Peer Comparison

Sample Size

6 peers

Industry Median PEG

1.40

25th Percentile

1.00

75th Percentile

1.51

Symbol	Company	PEG	P/E	Growth	vs RHHBF
AZN	AstraZeneca PLC	0.67	26.9	40.2%	—
GSK	GSK plc	1.00	14.3	14.4%	—
NVSEF	Novartis AG	1.39	20.8	15.0%	—
NVS	Novartis AG	1.40	21.6	15.4%	—
AZNCF	AstraZeneca PLC	1.51	31.0	20.5%	—

How to Interpret PEG Ratio

PEG < 1.0 — Potentially Undervalued. The stock may be priced below its earnings growth rate, suggesting a potential buying opportunity.

PEG 1.0–2.0 — Fairly Valued. The stock price is roughly in line with its earnings growth. A PEG of 1.0 is often considered "fair value."

PEG > 2.0 — Potentially Overvalued. The stock may be priced above what its earnings growth justifies.

Limitations:PEG ratios are less reliable for financial firms (earnings driven by interest margins), companies with negative/zero earnings growth, and hypergrowth companies (>100% growth) where the ratio may appear misleadingly low. Always use PEG alongside other valuation metrics.